You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
GeneDx reported third-quarter 2026 revenue of $123.1 million and adjusted net income of $8.6 million, raised full-year adjusted net income guidance to at least $12 million and reaffirmed revenue guidance of $475 million to $490 million.
GeneDx Holdings Corp. reported nine-month 2026 revenue of $339.8 million, up 11%, but a $93.4 million net loss and $72.0 million operating cash outflow.
GeneDx Holdings Corp. reported revenue of $123.1 million for the quarter ended September 30, 2026, up 5% year-over-year, and adjusted net income of $8.6 million, while maintaining full-year 2026 revenue guidance of $475 to $490 million.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. GeneDx delivered revenue, volume, margin, profitability and reimbursement improvements, and raised its full-year gross-margin and adjusted-net-income guidance. Key risks are lower volume and revenue-growth targets, revenue expected at the low end of guidance, prior-year margin and profitability pressure, a GAAP net loss, and a mid-single-digit 2027 PAMA revenue headwind.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted gross margin non-GAAP | 70.4% | the three months ended June 30, 2026 filing | — |
| Adjusted gross profit non-GAAP | $80.57M | Three months ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Gross profit 78.24M
+1.73M Depreciation and amortization
+561K Stock-based compensation
+47K Restructuring costs
= Adjusted gross profit 80.57M
|
|||
| Adjusted net income non-GAAP | $0.4M | second quarter of 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net (loss) income -17.74M
+6.71M Depreciation and amortization
+6.34M Stock-based compensation
+3.3M Restructuring costs
-220K Change in FV of financial liabilities
+2.02M Other
= Adjusted net income 411K
|
|||
| Adjusted net income (loss) non-GAAP | $411K | Three months ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net (loss) income -17.74M
+6.71M Depreciation and amortization expense
+6.34M Stock-based compensation expense
+3.3M Restructuring costs
-220K Change in fair value of financial liabilities
+1.19M Interest expense, net
+1.1M Non-core lease costs
+0K Impairment loss
+0K Loss on extinguishment of debt
-262K Other
= Adjusted net income (loss) 411K
|
|||
| Adjusted total operating expenses non-GAAP | $80.3M | second quarter of 2026 | — |
| Exome and genome test result volume | 30,785 | second quarter of 2026 | — |
| Exome and genome test revenue | $100.3M | second quarter of 2026 | — |
| Exome and genome tests as percentage of all test results | 49% | the three months ended June 30, 2026 filing | — |
| Exome and genome volume growth year-over-year | 32% | second quarter of 2026 | — |
| State Medicaid programs covering outpatient exome and/or genome sequencing | 39 | effective July 1, 2026 | — |
| Whole exome and genome sequencing revenue growth | 17% | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
WGS
this stock
GeneDx Holdings Corp.
|
$1.57B | -59.7% | +40.0% | — | 21.9% |
|
TMO
Thermo Fisher Scientific Inc.
|
$259.44B | +20.8% | +14.5% | 36.9 | 1.3% |
|
DHR
Danaher Corp
|
$163.94B | +1.8% | +8.5% | 38.1 | 1.2% |
|
IDXX
Idexx Laboratories Inc
|
$55.48B | +4.1% | +10.4% | 47.5 | 3.0% |
|
A
Agilent Technologies, Inc.
|
$49.04B | +27.8% | +6.4% | 34.2 | 1.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
GeneDx Holdings Corp. reported revenue of $123.1 million for the quarter ended September 30, 2026, up 5% year-over-year, and adjusted net income of $8.6 million, while maintaining full-year 2026 revenue guidance of $475 to $490 million.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| WGS | -16.0% | -17.7% | +5.9% | -24.2% | -59.7% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -18.6% | -16.5% | +5.4% | -24.0% | -70.4% |
